Browse Technologies
Keyword Search
Vaccines
Search Results
Displaying: 1 - 7 of 7 Results
Utilizing the herpes simplex virus-based vaccine vectors to develop a COVID-19 vaccine
Researchers in the lab of David Knipe have constructed the HSV-1 based vaccine vector HSV-1 d106S. The vector can express viral, bacterial, or cancer gene products and has been used to induce protective immunity in humanized mice against HIV and…
Investigators
- David Knipe
Novel adjuvants to enhance adaptive immune response of vaccines
Researchers in the lab of Ulrich von Andrian have discovered a novel adjuvanting behavior of a clinically approved and well-tolerated class of medicines known as bisphosphonates. The team is hoping to collaborate with manufacturers of COVID-19…
Investigators
- Ulrich von Andrian
Self-adjuvanting mRNA platform technology
Researchers in the lab of Prof. George Church at Harvard Medical School have developed a vaccine platform technology that can be applied to fields such as infectious diseases and oncology therapeutics. The team is looking to further demonstrate…
Investigators
- George Church
Membrane protein nanoparticles for antigen presentation
Researchers in the lab of Dr. James Chou have engineered a new way to display membrane proteins to enhance vaccine immunogenicity using functionalized nanoparticles. The lab has successfully displayed several viral peptides using this technique and…
Investigators
- James Chou
Platform for AAV Delivery to Skin
Emerging startup: A platform technology from George Church's lab enables delivery of gene therapy via the skin. (Image credit: Carl Schoellhammer, Denitsa Milanova, Humberto Trevino, Cody Cleveland, Jeff Wyckoff, Anna Mandinova, George Church,…
Investigators
- George Church
A fusion intermediate state of HIV-1 gp41, targeted by broadly neutralizing antibodies, for purposes of vaccination
HIV infection generally induces a strong antibody response to the envelope glycoprotein, the sole antigen on the virion surface. Most of the induced antibodies are ineffective in preventing infection, however, as they are either non-neutralizing or…
Investigators
- Stephen Harrison
- Gary Frey
- Bing Chen
Controlled delivery of TLR agonists in structural polymeric devices
Scientist at the Mooney lab demonstrated that three different types of pathogens could be incorporated to act as adjuvant in cancer vaccines. They have successfully incorporated three Toll-like receptor agonists (TLR) within a structural polymeric…
Investigators
- David Mooney
- Omar Ali
- Glenn Dranoff